© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 12, 1025-1032,
June 16, 1999
© 1999 Oxford University Press
Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality
Affiliations of authors: E. J. Feuer, B. F. Hankey, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; R. M. Merrill, Health Sciences Department, Brigham Young University, Provo, UT.
Correspondence to: Eric J. Feuer, Ph.D., National Institutes of Health, Executive Plaza North, Rm. 313, Bethesda, MD 20892.
BACKGROUND. The rise and fall of prostate cancer mortality correspond closely to the rise and fall of newly diagnosed cases. To understand this phenomenon, we explored the role that screening, treatment, iatrogenic (i.e., treatment-induced) deaths, and attribution bias (incorrect labeling of death from other causes as death from prostate cancer) have played in recent mortality trends. METHODS. Join point regression is utilized to assess the recent rise and fall in mortality and the relationship of total U.S. trends to those areas served by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Cancer Registry Program. Incidence-based mortality (IBM) is estimated with the use of prostate cancer data from the SEER Program to partition (from overall prostate cancer mortality trends) the contribution of cases diagnosed since the widespread use of prostate-specific antigen (PSA) testing starting in 1987. IBM is also used to examine the contribution of stage at diagnosis to the recent prostate cancer mortality trends. RESULTS. IBM for cases diagnosed since 1987 rose above the pre-1987 secular (i.e., background) trend, peaked in the early 1990s, and almost returned to the secular trend by 1994. This rise and fall of IBM track with the pool of prevalent cases diagnosed within the prior 2 years. IBM for cases diagnosed with metastatic disease fell starting in 1991, while IBM for those diagnosed with localized/regional disease was relatively flat. CONCLUSIONS. The rise and fall in prostate cancer mortality observed since the introduction of PSA testing in the general population are consistent with a hypothesis that a fixed percent of the rising and falling pool of recently diagnosed patients who die of other causes may be mislabeled as dying of prostate cancer. The decline in IBM for distant stage disease and flat IBM trends for localized/regional disease provide some evidence of improved prognosis for screen-detected cases, although alternative interpretations are possible.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Kvale, A. Auvinen, H.-O. Adami, A. Klint, E. Hernes, B. Moller, E. Pukkala, H. H. Storm, L. Tryggvadottir, S. Tretli, et al. Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries J Natl Cancer Inst, December 19, 2007; 99(24): 1881 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Ferlay, P Autier, M Boniol, M Heanue, M Colombet, and P Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann. Onc., February 7, 2007; (2007) mdl498v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Oberaigner, W. Horninger, H. Klocker, D. Schonitzer, W. Stuhlinger, and G. Bartsch Reduction of Prostate Cancer Mortality in Tyrol, Austria, after Introduction of Prostate-specific Antigen Testing Am. J. Epidemiol., August 15, 2006; 164(4): 376 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Field, D. S. M. Buist, C. Doubeni, S. Enger, H. Fouayzi, G. Hart, E. J. Korner, L. Lamerato, D. J. Bachman, J. Ellis, et al. Disparities and Survival Among Breast Cancer Patients J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 88 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jemal, E. Ward, X. Wu, H. J. Martin, C. C. McLaughlin, and M. J. Thun Geographic Patterns of Prostate Cancer Mortality and Variations in Access to Medical Care in the United States Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wilding and P. Remington Period Analysis of Prostate Cancer Survival J. Clin. Oncol., January 20, 2005; 23(3): 407 - 409. [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Feuer, R. Etzioni, K. A Cronin, and A. Mariotto The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing Statistical Methods in Medical Research, December 1, 2004; 13(6): 421 - 442. [Abstract] [PDF]
|
|
|
|
|
|
M. McNaughton-Collins, E. Walker-Corkery, and M. J. Barry Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 78 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Carter Prostate Cancers in Men with Low PSA Levels -- Must We Find Them? N. Engl. J. Med., May 27, 2004; 350(22): 2292 - 2294. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Godley, A. P. Schenck, M. A. Amamoo, V. J. Schoenbach, S. Peacock, M. Manning, M. Symons, and J. A. Talcott Racial Differences in Mortality Among Medicare Recipients After Treatment for Localized Prostate Cancer J Natl Cancer Inst, November 19, 2003; 95(22): 1702 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Draisma, R. Boer, S. J. Otto, I. W. van der Cruijsen, R. A. M. Damhuis, F. H. Schroder, and H. J. de Koning Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst, June 18, 2003; 95(12): 868 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein J. Clin. Oncol., April 1, 2003; 21(7): 1223 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Hoffman An Argument Against Routine Prostate Cancer Screening Arch Intern Med, March 24, 2003; 163(6): 663 - 665. [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, M. J. Kelley, R. C. Tate, and D. C. McCrory Screening for Lung Cancer: A Review of the Current Literature Chest, January 1, 2003; 123(1_suppl): 72S - 82S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu-Yao, P. C Albertsen, J. L Stanford, T. A Stukel, E. S Walker-Corkery, and M. J Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ, October 5, 2002; 325(7367): 740 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Andersen, P. Remington, A. Trentham-Dietz, and M. Reeves Assessing a Decade of Progress in Cancer Control Oncologist, June 1, 2002; 7(3): 200 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Gelmann, D. J. Steadman, J. Ma, N. Ahronovitz, H. J. Voeller, S. Swope, M. Abbaszadegan, K. M. Brown, K. Strand, R. B. Hayes, et al. Occurrence of NKX3.1 C154T Polymorphism in Men with and without Prostate Cancer and Studies of Its Effect on Protein Function Cancer Res., May 1, 2002; 62(9): 2654 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Vis Does PSA screening reduce prostate cancer mortality? Can. Med. Assoc. J., March 1, 2002; 166(5): 600 - 601. [Full Text] [PDF]
|
|
|
|
|
|
W. C. Black, D. A. Haggstrom, and H. Gilbert Welch All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, February 6, 2002; 94(3): 167 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, W. Cozen, L. Bernstein, R. K. Ross, and D. Deapen Changing Relationship Between Socioeconomic Status and Prostate Cancer Incidence J Natl Cancer Inst, May 2, 2001; 93(9): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Simoneau, E. W. Gerner, M. Phung, C. E. McLaren, and F. L. Meyskens Jr. {{alpha}}-Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial J Natl Cancer Inst, January 3, 2001; 93(1): 57 - 59. [Full Text] [PDF]
|
|
|
|
|
|
M. Baum, H G. Welch, T M Reynolds, A S Wierzbicki, A. G Threlfall, S. Collins, C. B J Woodman, M. P Coleman, D. Stockton, P. Babb, et al. Survival and reduction in mortality from breast cancer BMJ, December 9, 2000; 321(7274): 1470a - 1470. [Full Text]
|
|
|
|
|
|
B. F. Hankey, L. A. Ries, and B. K. Edwards The Surveillance, Epidemiology, and End Results Program: A National Resource Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1117 - 1121. [Full Text]
|
|
|
|
|
|
B. F. Hankey, E. J. Feuer, L. X. Clegg, R. B. Hayes, J. M. Legler, P. C. Prorok, L. A. Ries, R. M. Merrill, and R. S. Kaplan Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates J Natl Cancer Inst, June 16, 1999; 91(12): 1017 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Etzioni, J. M. Legler, E. J. Feuer, R. M. Merrill, K. A. Cronin, and B. F. Hankey Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part III: Quantifying the Link Between Population Prostate-Specific Antigen Testing and Recent Declines in Prostate Cancer Mortality J Natl Cancer Inst, June 16, 1999; 91(12): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|